関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|
| 反応物 | tert-Butyl (2R)-2-methylpiperazine-1-carboxylate | HCID 10262201 | — |
| 反応物 | 5-Bromo-2-ethoxyanisole | HCID 56737699 | — |
| 試薬 | Sodium t-butoxide | HCID 23676156 | — |
| 触媒 | Binap, (A+-)- | HCID 634876 | — |
| 触媒 | Palladium (II) acetate | HCID 4144353 | — |
| 溶媒 | Toluene | HCID 1140 | — |
| 生成物 | (3R)-1-(4-ethoxy-3-methoxyphenyl)-3-methylpiperazine | HCID 70277978 | 50.77% |
反応手順
Palladium(II) acetate (0.049 g, 0.22 mmol)and (R)-(+)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (0.108 g, 0.17 mmol) were added to 4-bromo-1-ethoxy-2-methoxybenzene (1 g, 4.33 mmol),(R)-1-N-Boc-2-methyl piperazine (0.867 g, 4.33 mmol) and Sodium tert- butoxide (0.624 g, 6.49 mmol) in anhydrous Toluene (20 mL) under argon. The resulting solution was stirred at reflux for18 hours. The reaction was allowed to cool to room temperature and diluted with dcm (50 ml). This was washed with water (2 x 50 ml), dried over sodium sulfate, filtered and the solvent removed under reduced pressure. The crude product was dissolved in hydrochloric acid solution in methanol (4N, 20 ml) and stirred at room temprature overnight. The solvent was removed under reduced pressure.The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7M NH3/MeOH and pure fractions were evaporated to dryness to afford (R)-1-(4-ethoxy-3-methoxyphenyl)-3-methylpiperazine (0.550 g, 50.8 %) as a yellow gum.
情報源と証拠
| 出典データセット | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-f42610ca5d2c4f39b60de444b5b2b82f |
|---|
| 出典メモ | 750 AstraZeneca ELN dataset |
|---|